Particle Data Platform

Second Date Update UPDATE: Hot to Huh

4/23/202619 min

We always talk about “the one who got away” but what about “The one who won’t go away?” We’re diving into it when Joe and Sabrina return to our show for a new Second Date Update UPDATE!

See omnystudio.com/listener for privacy information.

Clips

Transcript preview

First 90 seconds
  1. Geico Gecko0:00

    And now for a bit of breaking news between your breaking news, with me, the GEICO gecko. [upbeat jingle] Here are some things you ought to know today. People who switch their car insurance to GEICO save about $900 a year. Experts are calling that nice to know. Also, plants can hear when bees buzz. [bees buzzing] [laughs] My ficus just heard that. And finally, animal experts have confirmed that goats have regional accents. [goat bleating] I'm getting a hint of Irish there.

  2. Speaker 10:27

    It feels good to get good news. It feels good to GEICO.

  3. Speaker 20:29

    [upbeat jingle] Hey, everyone, it's Kal Penn. I'm inviting you to join the best-sounding book club you've ever heard with my podcast, Ear Say: the Audible and iHeart audiobook club. Every episode, I nerd out with amazing guests and dive into the best new audiobooks available on Audible. It's the book club for your ears. Listen to Ear Say, the Audible and iHeart audiobook club on the iHeartRadio app or wherever you get your podcasts.

  4. Speaker 30:57

    [upbeat jingle] Eczema is unpredictable, but you can flare less with EVQLUS, a once-monthly treatment for moderate to severe eczema. After an initial four-month or longer dosing phase, about 4 in 10 people taking EVQLUS achieved itch relief and clear or almost clear skin at 16 weeks, and most of those people maintained skin that's still more clear at one year with monthly dosing.

  5. Speaker 41:19

    EVQLUS, librocixumab-LBKZ, a 250 milligram per two milliliter injection, is a prescription medicine used to treat adults and children 12 years of age and older who weigh at least 88 pounds or 40 kilograms with moderate

We value your privacy

We use cookies to understand how you use our platform and to improve your experience. Click "Accept All" to consent, or "Decline non-essential" to opt out of non-essential cookies. Read our Privacy Policy.